Kailera Therapeutics Inc (KLRA) Stock Price, Quote & News

Company Profile

Kailera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company developing therapies for obesity and related conditions. The company develops clinical- and preclinical-stage therapies, with a product pipeline that includes injectable peptides, oral peptides, and oral small molecules. Key programs include KAI-9531, an injectable GLP-1/GIP receptor dual agonist; KAI-7535, an oral small molecule GLP-1 receptor agonist; and KAI-4729, an injectable GLP-1/GIP/glucagon receptor tri-ag...

Industry: Biotechnology

Sector: Healthcare

Phone: 781 317 0290

Website: www.kailera.com

Address:

180 Third Avenue, 4th Floor, Waltham, United States

biolover Jul. 30 at 10:45 PM

$VKTX to be fair to the CEO , vanquish enrollment took 4.5 months for 4600 pts. The studios running well. Medpace is the CRO $KLRA enrollment for phase 3 ( smaller trials ) commenced Dec 2025 and has not finished yet. $GPCR has not started phase 3 yet.

0 · Reply

stockydennis Jul. 29 at 2:04 PM

$KLRA quiet 🤫

0 · Reply

stockydennis Jul. 27 at 5:24 PM

$KLRA ✊🏾

0 · Reply

stockydennis Jul. 24 at 5:37 PM

$KLRA $PFE glp-1 war

0 · Reply

JohnnyVacs Jul. 24 at 5:17 PM

$VKTX $KLRA & $GPCR catching up in market cap! Maybe BL can learn a couple things from them?

0 · Reply

JohnnyVacs Jul. 23 at 6:57 PM

$VKTX It is. It’s called they aren’t selling and thats all anyone wants here. Funny how all other GLP-1 other than $KLRA are doing just fine today. $LLY $NVO $GPCR all perfectly fine. This drop is VIKING SPECIFIC and will continue to drop back to $30 with the CLOWN🤡 CEO in charge. This stock is easy. Buy at $30 and sell high $30’s. Rinse repeat. Brian Lian is a disaster to this company business wise. Wait till he sells shares in a couple days. Then it drops even more.

0 · Reply

JohnnyVacs Jul. 23 at 5:34 PM

$VKTX even $KLRA is recovering😂 but someone knows something. Gonna accelerate into close and almost hit $35. @Stockman824 where have you been clown boy? Still giving motivational speeches posts? 🤡🤡🤡

0 · Reply

JohnnyVacs Jul. 22 at 3:03 PM

$VKTX $KLRA TOO 😂😂😂😂😂😂

0 · Reply

Ataifanboymentalhealthz Jul. 7 at 11:44 PM

$KLRA $VKTX exactly right. Check out $BMEA very early but their GLP-1RA is same structure as foundayo (orforglipron) but better pk profile. Side effects so low they able to possibly achieve a first titration first week . 100 mg first week and then 400 mg per week next 3 weeks . Without doing this in cytologus monkeys they got 15%? Weight loss in 28 days. I can’t wait to see the weight loss with this instant titration scheme in Q3 2026 any day now

0 · Reply

JFais Jul. 7 at 9:57 PM

$KLRA - a timely reminder that not all GLP-1s are created equal... Also of the relevance of $VKTX improved tolerability thesis

3 · Reply

Kailera Therapeutics announces positive Phase 3 data for weight loss drug

Jul 7, 2026, 7:09 AM EDT - 4 weeks ago

Kailera's GLP-1 drug meets main goal of late-stage trials

2026-06-29T11:45:19.000Z - 5 weeks ago

Kailera appoints Kathleen Tregoning as chief corporate affairs officer

Jun 29, 2026, 7:30 AM EDT - 5 weeks ago

Kailera Therapeutics Appoints Kathleen Tregoning as Chief Corporate Affairs Officer

Jun 25, 2026, 11:31 AM EDT - 6 weeks ago

Biotech ETF Index Surges 10% After Rebalance

ALKS APGE DFTX DYN KYMR MANE MIRM

Jun 5, 2026, 7:32 PM EDT - 2 months ago

Hengrui Pharma and Kailera Therapeutics Present Ribupatide Clinical Data at ADA 2026

Jun 4, 2026, 10:30 AM EDT - 2 months ago

Kailera Therapeutics Transcript: Jefferies Global Healthcare Conference 2026

May 28, 2026, 4:05 PM EDT - 2 months ago

Kailera Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference

May 26, 2026, 4:02 PM EDT - 2 months ago

Kailera Reports First Quarter 2026 Financial Results and Provides Clinical Data Updates

May 26, 2026, 4:00 PM EDT - 2 months ago

Kailera Therapeutics Earnings release: Q1 2026

May 26, 2026, 4:00 PM EDT - 2 months ago

Kailera Therapeutics Quarterly report: Q1 2026

May 26, 2026, 7:00 AM EDT - 2 months ago

Kailera Therapeutics Slides: Company presentation

May 13, 2026, 7:30 AM EDT - 3 months ago

Hengrui Pharma and Kailera Therapeutics Announce Clinical Data Presentations at the American Diabetes Association 86th Scientific Sessions

2026-05-12T15:50:12.000Z - 3 months ago

Kailera Therapeutics initiated with an Outperform at Evercore ISI

2026-05-12T11:41:46.000Z - 3 months ago

Kailera Therapeutics initiated with an Outperform at Leerink

LLY NVO

2026-05-12T09:37:06.000Z - 3 months ago

Kailera Therapeutics initiated with a Buy at TD Cowen

2026-05-12T09:15:10.000Z - 3 months ago

Kailera Therapeutics initiated with an Outperform at William Blair

2026-05-12T09:10:43.000Z - 3 months ago

Kailera Therapeutics initiated with an Overweight at JPMorgan

2026-05-12T09:06:18.000Z - 3 months ago

Kailera Therapeutics initiated with a Buy at Jefferies

Apr 20, 2026, 4:05 PM EDT - 3 months ago

Kailera Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

2026-04-17T18:40:18.000Z - 4 months ago

Kailera Stock (KLRA) Rockets 68% after IPO in Race for $150B Obesity Market

AMGN GPCR LLY PFE

Apr 17, 2026, 1:41 PM EDT - 4 months ago

Kailera surges over 60% in Nasdaq debut as weight-loss drug race heats up

2026-04-17T17:30:55.000Z - 4 months ago

Kailera Therapeutics opens at $26, IPO priced at $16 per share

2026-04-17T15:45:23.000Z - 4 months ago

Kailera Therapeutics indicated to open at $21, IPO priced at $16

2026-04-17T14:40:16.000Z - 4 months ago

Kailera Therapeutics indicated to open at $24, IPO priced at $16

2026-04-17T00:05:37.000Z - 4 months ago

Kailera Therapeutics 39.06M share IPO priced at $16.00

Apr 16, 2026, 7:25 PM EDT - 4 months ago

Kailera Therapeutics Announces Pricing of Initial Public Offering

Apr 13, 2026, 8:00 AM EDT - 4 months ago

Kailera Therapeutics Registration statement: Registration filing

Mar 27, 2026, 4:15 PM EDT - 4 months ago

Kailera Therapeutics files for US IPO

Mar 27, 2026, 4:02 PM EDT - 4 months ago

Kailera Therapeutics IPO Registration Document (S-1)

biolover Jul. 30 at 10:45 PM

0 · Reply

stockydennis Jul. 29 at 2:04 PM

$KLRA quiet 🤫

0 · Reply

stockydennis Jul. 27 at 5:24 PM

$KLRA ✊🏾

0 · Reply

stockydennis Jul. 24 at 5:37 PM

$KLRA $PFE glp-1 war

0 · Reply

JohnnyVacs Jul. 24 at 5:17 PM

$VKTX $KLRA & $GPCR catching up in market cap! Maybe BL can learn a couple things from them?

0 · Reply

JohnnyVacs Jul. 23 at 6:57 PM

0 · Reply

JohnnyVacs Jul. 23 at 5:34 PM

0 · Reply

JohnnyVacs Jul. 22 at 3:03 PM

$VKTX $KLRA TOO 😂😂😂😂😂😂

0 · Reply

Ataifanboymentalhealthz Jul. 7 at 11:44 PM

0 · Reply

JFais Jul. 7 at 9:57 PM

$KLRA - a timely reminder that not all GLP-1s are created equal... Also of the relevance of $VKTX improved tolerability thesis

3 · Reply

JFais Jul. 7 at 9:51 PM

$KLRA - good reminder that not all GLP-1s created equal... Reminder of the relevance of $VKTX improved tolerability thesis

0 · Reply

Jten10 Jul. 7 at 4:12 PM

$VKTX What’s going on with $KLRA?

3 · Reply

LLLJJJ Jul. 6 at 8:26 AM

$KLRA Whether $PFE will buy $KLRA ???????

0 · Reply

MikeyMcDermott Jul. 4 at 12:23 AM

Paul Hastings, eh? $SPRO $LGND ? $XOMA ? $KLRA $GSK ?

0 · Reply

nlrmandate Jun. 24 at 9:32 PM

@IM11 not raining on anyone's parade. All three of $VKTX $GPCR and $KLRA will be bought by mid 2027 IMO. There are several BP who wish to play in the obesity sandbox and these three are the only clinical biotechs in the weight loss sector with seriously good/great pipelines. And, they're all different enough from each other to attract buyers. Long and insanely

0 · Reply

biolover Jun. 24 at 6:30 PM

The volume story is still there and likely hiding news beyond $VKTX amylin is not the whole story? anemic volume for $KLRA and $GPCR. ? Why it is not a fair game and others will know early ?

2 · Reply

Bagholding_VKTX Jun. 24 at 2:43 AM

$VKTX I agree, today's movement was clearly from Viking specific flows. What I noticed, and some of you may also have noticed, is $KLRA and $GPCR 's movement compared to Viking. Both surged, as expected, in tandem with VKTX, in the last few days. However, today, KLRA fell sharply and GPCR is flat. In addition, please zoom out on Viking's chart. The recent surge is one of the steepest inclines (excluding data releases), suggesting that there were heavy, heavy buying flows in the past few days. Moreover, amylin's announcement still has not come. This is not a coincidence. The inflows into Viking and outflows from KLRA and GPCR could mean institutions may think a partnership/BO could be coming soon, with Viking. It does not mean there WILL be a partnership/buyout. But, everything always somehow leaks. It is extremely likely that this leak may have been that there are currently discussions going on and that they are getting more serious. I remain extremely bullish. $350 is likely

0 · Reply

History101 Jun. 19 at 8:49 PM

$KLRA 133 watching 6/19/2026

0 · Reply

JohnnyVacs Jun. 18 at 7:59 PM

$VKTX there you go. XBI spiking end of day and this going the opposite. $KLRA spiking. KLRA announcement coming monday. Another one BO before VKTX. Was outperforming the XBI all day and dumps on no volume. It must really be fun to be a short on VKTX. Another day the index outperforms VKTX. Usually Bio’s spike into close for covering reasons. Not VKTX. People don’t want to hold it over the weekend because it can dump 50% like its nothing.

0 · Reply

biolover Jun. 18 at 7:35 PM

$VKTX rumors $ABBV jets clustered somewhere remote 😂. I personally don’t beleive Abbv will wait long. Could be Vk could be $KLRA These calls could go up 100.000% last 2 year sentiment suggests otherwise but u never know ..

0 · Reply

biolover Jun. 16 at 10:57 AM

$VKTX Trump JR at $NVO headquarters..and speculation why ? One discussed possibility is needing help with FTC .. the real question is who really needs who ? Novo or Viking ?— could be $KLRA as well although in this case novo will rely on Chinese pts tolerability data.

1 · Reply

PlutoAnalyses Jun. 11 at 3:29 PM

STRUCTURE THERAPEUTICS The full analysis of $GPCR is now available online on my Substack! If you're interested in the GLP-1 market or companies like $VKTX or $KLRA, this post is worth a read. I've found that safety might matter more than efficacy when it comes to GLP-1s, which is where GPCR really stands out. You can check out the article for free here: https://open.substack.com/pub/plutoanalyses/p/structure-therapeutics-analysis-whats?utm_source=app-post-stats-page&r=5e6tza&utm_medium=ios $XBI $IBB

0 · Reply

Market Cap	2.42B
Revenue (ttm)	0.00
Net Income (ttm)	-148.96M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	276,200
Avg Vol	748,886
Day's Range	N/A - N/A
Shares Out	129.57M
Stochastic %K	78%
Beta	N/A
Analysts	Strong Sell
Price Target	$42.75